In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from Octane’s Ophthalmology Technology Forum with guests Tibor Juhasz, PhD, Richard L. Lindstrom, MD, Sumit “Sam” Garg, MD and Jean-Pierre Hubschman, MD.

• Welcome to the Eyeluminaries podcast 00:05
• Review of episode 33 00:49
• Intro of Tibor Juhasz, PhD 01:35
• Tell us about your background and how you changed LASIK, cataract and glaucoma surgery. 02:27
• How is ViaLase impacting glaucoma treatment? 06:55
• How the treatment works 08:24
• The importance of having a good team 11:02
• Intro of Richard L. Lindstrom, MD 12:58
• What is your perspective on what is happening today and what changes are you hoping for? 14:28
• Integrated eye care delivery 17:00
• Dentistry, a future model for eye care 17:50
• Post-graduate medical education is changing 19:09
• Was there a technology that you thought was a slam dunk and failed? 23:01
• Any technology that you didn’t expect to take off? 24:37
• Intro of Sumit “Sam” Garg, MD 26:58
• What do you see changing in ophthalmology residency programs around the country? 28:52
• How do you instruct young physicians to be collaborative in care? 30:42
• If you weren’t a cornea specialist (or a model) what would you be? 32:10
• Advice for young ophthalmologists today? 33:42
• Share a Jim Mazzo story with us! 35:28
• Intro of Jean-Pierre Hubschman, MD 37:07
• Why did you, with a robotics company, decide to start in cataract surgery? 38:23
• How do you become more efficient in robotic surgery? 41:00
• How do we work on the economic side of this? 43:38
• What’s it like running a company vs being a retina surgeon? 44:46
• Give us your feedback 48:16
• Thanks for listening 48:30

Tibor Juhasz, PhD, is the founder and CEO of ViaLase Inc. He was also the co-founder of IntraLase and LenS.

Richard L. Lindstrom, MD, is the founder and an attending surgeon at Minnesota Eye Consultants, an adjunct professor emeritus at the University of Minnesota, department of ophthalmology as well as the global chief medical editor of Ocular Surgery News.

Sumit “Sam” Garg, MD, is the medical director at the Gavin Herbert Eye Institute at UC Irvine.

Jean-Pierre Hubschman, MD, is the co-founder and CEO of Horizon Surgical Systems.

We’d love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.

Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm disclosures for Garg, Hubschman, Juhasz, and Lindstrom at the time of publication.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news from Washington with guest Mark Leahey.

• Welcome to the Eyeluminaries podcast :02
• Review of episode 31 :40
• BVI Medical names a new CCO 2:20
• GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions 5:42
• Tenpoint submits new drug application for presbyopia combination therapy 7:33
• Alcon acquires majority stake in Aurion Biotech 10:29
• FDA approves Encelto for macular telangiectasia type 2 14:50
• Intro of Mark Leahey 17:28
• There is a lot of attention on the HHS restructuring. What are your insights into what has happened to date, and what could happen in the future? 20:10
• What do you think about the leadership? 23:44
• Let’s talk about sustainability. Tell us about the medical device industry’s collective interest and challenges in regard to moving toward environmentally sustainable initiatives. 24:59
• Let’s talk about leadership: Dr. Marty Makary and Dr. Oz. 27:53
• Tariffs are an evolving subject. What is the impact on the medical community? What is your impression on how these will affect us in the short term and long term? 33:20
• Preview of episode 33 39:27
• Give us your feedback 40:23
• Team Mah-rvel: the Party for a Purpose 40:41
• Thanks 40:58

John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Mark Leahey is the president and CEO for the Medical Device Manufacturers Association (MDMA).

Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.

We’d love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.

Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Leahey.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Steven Dell, MD, about his career and the creation of markets in the field of ophthalmology.

• Welcome to the Eyeluminaries podcast :02
• Review of episode 29 1:28
• Bausch + Lomb acquires Elios Vision 2:07
• ImprimisRx awarded $34.9 million in trademark infringement suit against OSRX 5:00
• Study of atropine-based myopia treatment fails to meet primary efficacy endpoint 7:31
• Intro of Steven Dell, MD 11:20
• You have created markets with new technologies and companies. Can that continue in today’s market? 13:28
• Dell discusses presbyopia market development. 14:11
• You created a questionnaire that you used in your practice, which has become known as the Dell Questionnaire. What do we need to do better in treating our cataract patients? 16:20
• What technologies are going to be the most important in the future? 20:24
• What has changed in your office environment, i.e., the role of ODs, admin, staff? 22:00
• Dell discusses Lindstrom’s Integrated Eye Care Delivery Model. 23:08
• What advice would you give a younger Steven Dell? 27:16
• Neurotech Pharmaceuticals announced that chief commercial officer Scott Hunter died on Dec. 3. 33:06
• Give us your feedback 34:43
• Thanks 34:51

Steven J. Dell, MD, is a board-certified ophthalmologist in Austin and the Medical Director of Dell Laser Consultants.

John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.

We’d love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.

Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Dell at the time of publication.

In this episode, Jim Mazzo and John A. Hovanesian, MD, FACS, are live from Eyecelerator with Mend the Gap hosts Susan MacDonald, MD, and Cathleen McCabe, MD, discussing their humanitarian work.

• Welcome to the Eyeluminaries podcast :02
• In this episode :31
• Intro of Susan MacDonald, MD, and Cathleen McCabe, MD 1:00
• What started you on this journey to do humanitarian work? 2:18
• MacDonald discusses the role of parents in defining of happiness. 7:47
• Hovanesian discusses the background of his humanitarian work in Armenia. 8:24
• What about the funding of these humanitarian projects? 9:38
• What are your stories from doing humanitarian work? 10:59
• What advice to do you have for physicians who want to get involved in humanitarian work? 15:43
• Hovanesian discusses the commonalities in MacDonald and McCabe’s humanitarian missions. 19:11
• McCabe discusses the commonalities in Hovanesian and MacDonald’s humanitarian missions. 19:38
• MacDonald discusses how her humanitarian work began. 20:16
• Thank you. 23:49
• MacDonald talks about the ophthalmic industry and their contribution to humanitarian work. 24:39
• McCabe discusses ways physicians can get involved in humanitarian work without having to travel overseas. 25:30
• Visit ACE Global, Cybersight or Operation Sight to get involved. 25:38
• Mend the Gap podcast 27:37
• Preview of episode 30 29:05
• Give us your feedback 29:25
• Thanks 30:05

John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Susan MacDonald, MD, is president of Eye Corps and associate clinical professor at Tufts School of Medicine.

Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.

Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL.

We’d love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.

Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. MacDonald and McCabe report no relevant financial disclosures.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Tom Mitro about his career and impact in ophthalmology.

• Welcome to the Eyeluminaries podcast :02
• Review of episode 26 :58
• FDA grants fast track designation to brepocitinib for noninfectious uveitis 1:42
• I. Howard Fine, MD, esteemed ophthalmologist, dies 3:54
• First subjects dosed in phase 3 trial of phentolamine ophthalmic solution for presbyopia 5:48
• LENZ Therapeutics submits NDA for drops to treat presbyopia 7:57
• Intro of Tom Mitro 10:40
• Tell us about your journey in ophthalmology 12:38
• Tell us about the new dry eye drug from Signal 12. 15:53
• How much sensation is on the forehead if the drug is well tolerated? 24:13
• What are your thoughts on the current ophthalmology market? 26:01
• Tell us a funny story about Jim Mazzo and about John Hovanesian. 28:51
• Preview of episode 29 33:25
• Give us your feedback 34:34
• Thanks 34:50

John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.

Tom Mitro is the president and chief operating officer for Aerie Pharmaceuticals.

We’d love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.

Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Mitro at the time of publication.

In this special throwback episode, John Hovanesian, MD, and Jim Mazzo revisit their discussions with Steven Schwartz, MD, and Sean Ianculev, MD, about innovations, treatments and entrepreneurship in eye care.

• Welcome to the Eyeluminaries podcast :10
• About Steven Schwartz, MD 2:32
• The interview 3:16
• Discussion of current innovation in cataract surgery including use of AI, imaging and robotics 4:05
• Discussion on Schwartz’s involvement in Neurotech MacTel cell-based treatment 6:32
• Advances and disappointments in retinal disease treatments? 10:32
• How do companies come back from disappointing trial results? 11:07
• Why do retina discoveries take so long to develop? 14:31
• New dry AMD treatments in development? 15:58
• Drug delivery technologies and will retina specialists use them?
• What do you predict we’ll be doing differently in medicine 2 years from now and why? 22:00
• What’s the difference between a retina and cornea specialist? 23:52
• Introduction of Sean Ianchulev, MD, MPH 25:38
• The interview 26:29
• Impact on Google Glass 30:27
• What innovations are you proud of and what projects are you excited about? 35:31
• What advice do you have for new entrepreneurs? 42:16
• How do you balance your work life and your home life? 45:25
• Legends in the field of ophthalmology 47:39
• Give feedback at eyeluminaries@healio.com 49:36
• Thanks for listening 49:57

Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health.

John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO.

Steven Schwartz, MD, is the Ahmanson professor in ophthalmology and the chief of the retina division at the UCLA Jules Stein Eye Institute and the director of the Diabetic Eye Disease and Retinal Vascular Center.

We’d love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Schwartz via email at schwartzpatients@jsei.ucla.edu. You can find Dr. Ianchulev on LinkedIn.

Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Schwartz is the co-founder of Horizon Surgical; member on the National Eye Institute Audacious Initiative Scientific executive committee and reports receiving grants from Neurotech, Optos/Nikon, the California Institute of Regenerative Medicine; and investigator fees from Neurotech and Optos/Nikon and the California Institute of Regenerative Medicine.